1. Home
  2. Directory
  3. Nevada
  4. Las Vegas
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1922052281

DR. MEHER YEPREMYAN MD
Prescription History 1922052281
Ophthalmology in Las Vegas, NV


Quality Rating: 95.16 out of 100 score

NPI Status: Active since May 20, 2006

Contact Information

653 N TOWN CENTER DR STE 518
LAS VEGAS, NV
ZIP 89144
Phone: (702) 369-0200
Fax: (702) 243-8383

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MEHER YEPREMYAN MD, an active Ophthalmology specialist practicing in Las Vegas, NV. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 390 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisolone Acetate, which accounts for 149 claims alone.

Medication Index

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 13
30-Day Fills 27.0
Days Supply 811
NV State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills123.0
Peer Average Days Supply3,673
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.8% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.82

State Avg Cost Per Claim

$29.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 27
30-Day Fills 71.4
Days Supply 2,142
NV State Average Benchmarks
Peer Average Claims98.0
Peer Average 30-Day Fills223.0
Peer Average Days Supply6,670
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.4% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $482.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.86

State Avg Cost Per Claim

$29.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Ketorolac Tromethamine

Generic Formulation: Ketorolac TromethamineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 74
30-Day Fills 108.9
Days Supply 3,115
NV State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills80.6
Peer Average Days Supply1,914
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,239.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.26

State Avg Cost Per Claim

$23.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Therapeutic Applications

This medication is used to temporarily relieve itching eyes caused by seasonal allergies. It is also used to prevent and treat eye swelling due to a certain type of eye surgery (cataract removal). Ketorolac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking certain natural substances in your body to reduce pain and swelling.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 85
30-Day Fills 85.4
Days Supply 1,489
NV State Average Benchmarks
Peer Average Claims103.0
Peer Average 30-Day Fills105.5
Peer Average Days Supply1,584
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,595.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.53

State Avg Cost Per Claim

$31.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 149
30-Day Fills 209.2
Days Supply 5,866
NV State Average Benchmarks
Peer Average Claims134.0
Peer Average 30-Day Fills171.0
Peer Average Days Supply4,381
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,101.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.08

State Avg Cost Per Claim

$50.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 42
30-Day Fills 79.8
Days Supply 2,371
NV State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills203.5
Peer Average Days Supply6,028
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.3% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $515.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.27

State Avg Cost Per Claim

$21.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MEHER YEPREMYAN MD provides transparency into local medical care patterns within Las Vegas, NV.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.